Comparative Pharmacology
Head-to-head clinical analysis: ANOQUAN versus LIDOSITE TOPICAL SYSTEM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANOQUAN versus LIDOSITE TOPICAL SYSTEM KIT.
ANOQUAN vs LIDOSITE TOPICAL SYSTEM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses.
100 mg orally twice daily
Apply up to 3 patches topically once daily for up to 12 hours per day. Maximum 3 patches (210 mg lidocaine) per day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
1.5-2 hours (terminal); prolonged in hepatic dysfunction or heart failure
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
Renal (80-90% as metabolites, <10% unchanged), biliary/fecal (minor, <5%)
Category C
Category C
Local Anesthetic
Local Anesthetic